ly3556050

LY3556050 is an experimental small molecule drug being developed for the treatment of chronic pain conditions. It acts as a selective agonist of the somatostatin receptor subtype 4 (SSTR4), which is implicated in pain modulation pathways. The drug has been evaluated in clinical trials for diabetic peripheral neuropathic pain (DPNP), osteoarthritis pain, and chronic low back pain. In DPNP studies, LY3556050 demonstrated statistically significant improvements in pain compared to placebo at Week 8 when administered at 600 mg twice daily[6][10]. However, it did not show superiority over placebo for osteoarthritis or chronic low back pain in Phase 2 studies[8]. The most common adverse events were gastrointestinal-related (constipation, nausea, diarrhea) and generally mild to moderate in severity[6][8].

Other names

LY3556050LY-3556050LY 3556050CNTX-0290CNTX0290CNTX 0290mazisotine